ClinicalTrials.gg

Program

NA-931

A development code. Also written as “NA-931 150 mg + no Tirzepatide”, “NA-931, dose 1, daily and orally” and “NA-931, dose2, daily and orally”.

Its studies are mostly in Obesity, led by Biomed Industries.

Furthest: phase 2, since Aug 16, 20243 company-led studies, 1 open or runningNext primary completion: Aug 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biomed Industries31 open or runningphase 2since Aug 16, 2024Aug 16, 2024Aug 15, 2027phase 2 · NCT06732245

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2024First study: phase 2 study in Weight LossFirst studyNCT06564753 · 126 enrolled · Australia
  2. Sep 24, 2024Phase 1 study in OverweightNCT06615700 · 74 enrolled · Australia
  3. Dec 9, 2024Phase 2 study in ObesityNCT06732245 · 224 planned · United States, Australia, New Zealand

Ahead

  1. Aug 15, 2027Primary completion: phase 2 study in ObesityNCT06732245

TargetBeta

“NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 (IGF-1), Glucagon-like Peptide-1 (GLP-1), Gastric Inhibitory Polypeptide (GIP) and Glucagon.”study text, by rule · the study

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06732245Obesity · United States, Australia, New Zealand2Not yet recruitingAug 15, 2027224
NCT06615700Overweight · Australia1CompletedAug 12, 202474
NCT06564753Weight Loss · Australia2CompletedFeb 27, 2025126

How it is read

Names in the registry

  • “NA-931”, 7 entries
  • “NA-931 150 mg + no Tirzepatide”, 1 entry
  • “NA-931, dose 1, daily and orally”, 1 entry
  • “NA-931, dose2, daily and orally”, 1 entry
  • “NA-931 dose 3, daily and orally”, 1 entry

Codes read as this program: NA931.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.